Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies

The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 [NCT00360568] or Study S187.3.004 [NCT00335153]).

Study Overview

• Status: Completed
• Conditions: Advanced Parkinson's Disease
• Intervention / Treatment: Drug: Levodopa-Carbidopa Intestinal Gel (LCIG); Device: CADD-Legacy® 1400 ambulatory infusion pump; Device: Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)

• Study Type: Interventional
• Enrollment (Actual): 262
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Westmead, New South Wales, Australia, 2145
      • Westmead Hospital /ID# 50081
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • Royal Adelaide Hospital /ID# 50083
  • Victoria
    • Heidelberg, Victoria, Australia, 3084
      • Austin Hospital /ID# 50082
• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 2B7
      • University of Alberta /ID# 78476
  • Ontario
    • Toronto, Ontario, Canada, M5T 2S8
      • Toronto Western Hospital /ID# 75913
  • Quebec
    • Montréal, Quebec, Canada, H2X 0A9
      • CHUM - Notre-Dame Hospital /ID# 74513
• Czechia
  • Brno, Czechia, 656 91
    • Fakultni Nemocnice u Svate Anny /ID# 50085
  • Hradec Králové, Czechia, 500 05
    • Fakultni nemocnice Hradec Kralove /ID# 50088
  • Pardubice, Czechia, 532 03
    • Pardubicka krajska nemocnice, a.s.
  • Praha, Czechia, 128 21
    • Vseobecna fakultni nemocnice v Praze /ID# 50086
  • Praha, Czechia, 150 06
    • Fakultni Nemocnice v Motole /ID# 50084
• Israel
  • Tel-Aviv, Israel, 64239
    • Tel Aviv Sourasky Medical Center /ID# 50089
• New Zealand
  • Auckland, New Zealand, 1023
    • Auckland City Hospital /ID# 50093
  • Christchurch, New Zealand, 8011
    • New Zealand Brain Research Institute/ID# 50090
  • Wellington, New Zealand, 6021
    • Wellington Hospital /ID# 50092
  • Waikato
    • Hamilton, Waikato, New Zealand, 3240
      • Waikato Hospital /ID# 50091
• Poland
  • Lodzkie
    • Łódź, Lodzkie, Poland, 93-113
      • Miejskie Centrum Medyczne im. dr. Karola Jonschera w Lodzi /ID# 50096
  • Wielkopolskie
    • Poznań, Wielkopolskie, Poland, 61-485
      • NZOZ Centrum Medyczne HCP /ID# 50094
• Portugal
  • Coimbra, Portugal, 3000-075
    • Hospitais da Universidade de Coimbra /ID# 50098
  • Lisboa, Portugal, 1649-035
    • Hospital de Santa Maria /ID# 50099
  • Porto, Portugal, 4200-319
    • Centro Hospitalar Universitario de Sao Joao, EPE /ID# 50101
• Russian Federation
  • Kazan, Russian Federation, 420097
    • Scientific Research Medical Complex Your Health /ID# 50104
  • Moscow, Russian Federation, 125367
    • Institution of the Russian Academy of Medical Sciences Scientific Centre of Neurology /ID# 50102
  • Saint Petersburg, Russian Federation, 194044
    • Military Medical Academy n.a. Kirov /ID# 50103
  • Saint Petersburg, Russian Federation, 197022
    • I.P. Pavlov First St. Petersburg State Medical University /ID# 50107
  • Saint Petersburg, Russian Federation, 197706
    • City Clinical Hospital #40 /ID# 50106
• Thailand
  • Bangkok, Thailand, 10330
    • King Chulalongkorn Mem Hosp /ID# 50108
  • Bangkok, Thailand, 10700
    • Siriraj Hospital /ID# 50109
• United Kingdom
  • Liverpool, United Kingdom, L9 7LJ
    • The Walton Centre NHS Foundation /ID# 50003
  • London, United Kingdom, WC1N 3BG
    • National Hospital for Neurology & Neurosurgery
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • University of Alabama at Birmingham /ID# 49941
  • California
    • Encinitas, California, United States, 92024
      • The Research Center of Southern California /ID# 49928
    • Fountain Valley, California, United States, 92708
      • The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 49915
    • Los Angeles, California, United States, 90033
      • Universtiy of Southern California /ID# 49913
  • Colorado
    • Englewood, Colorado, United States, 80113
      • Colorado Neurological Institute /ID# 49927
  • District of Columbia
    • Washington, District of Columbia, United States, 20007
      • Georgetown University Hospital /ID# 49931
  • Florida
    • Bradenton, Florida, United States, 34205
      • Bradenton Research Center, Inc /ID# 49929
    • Fort Lauderdale, Florida, United States, 33308
      • Neurologic Consultants, PA /ID# 49918
    • Gainesville, Florida, United States, 32610
      • University of Florida - Archer /ID# 49935
    • Jacksonville, Florida, United States, 32209
      • University of Florida /ID# 49922
    • Port Charlotte, Florida, United States, 33980
      • Charlotte Neurological Service /ID# 49916
    • Tampa, Florida, United States, 33612
      • University of South Florida /ID# 49919
  • Georgia
    • Augusta, Georgia, United States, 30912
      • Georgia Regents University /ID# 49938
  • Illinois
    • Chicago, Illinois, United States, 60611-2927
      • Northwestern University Feinberg School of Medicine /ID# 49944
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center /ID# 49930
  • Kentucky
    • Lexington, Kentucky, United States, 40536
      • University of Kentucky Chandler Medical Center /ID# 49940
  • Louisiana
    • Shreveport, Louisiana, United States, 71130
      • Louisiana State Univ HSC /ID# 49945
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • Univ Maryland School Medicine /ID# 49934
    • Baltimore, Maryland, United States, 21287
      • Johns Hopkins University /ID# 49937
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University-School of Medicine /ID# 49933
  • Nebraska
    • Omaha, Nebraska, United States, 68198
      • University of Nebraska Medical Center /ID# 49911
  • New York
    • Manhasset, New York, United States, 11030
      • North Shore University Hospital /ID# 49932
    • New York, New York, United States, 10029
      • The Mount Sinai Hospital /ID# 49942
    • New York, New York, United States, 10032-3725
      • Columbia Univ Medical Center /ID# 49943
  • North Carolina
    • Raleigh, North Carolina, United States, 27607
      • Raleigh Neurology Associates /ID# 49923
    • Winston-Salem, North Carolina, United States, 27157
      • Wake Forest Univ HS /ID# 49939
  • Ohio
    • Cincinnati, Ohio, United States, 45267-0585
      • University of Cincinnati /ID# 49914
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic Main Campus /ID# 76173
  • Vermont
    • Burlington, Vermont, United States, 05401-1473
      • University of Vermont Medical Center /ID# 49912
  • Washington
    • Kirkland, Washington, United States, 98034
      • King County Public Hospital /ID# 49917
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Froedtert Memorial Lutheran Hospital /ID# 49924

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The participant should have completed participation in Study S187.3.003 or S187.3.004; and, in the opinion of the Principal Investigator, would benefit from long-term treatment with LCIG.
• For Canada, participants will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study.
• The participant must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study related procedures. If the participant does not have the capacity to provide informed consent, full informed consent must be obtained from the participant's legally authorized representative. Consenting will be performed according to local regulations.

Exclusion Criteria:

• Medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be clinically significant and which could interfere with the participant's participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Levodopa-Carbidopa Intestinal Gel; Initial dosing is based on the dosing regimen that the participant received during the previous LCIG study. Dosing is individually optimized and can be adjusted at any time during the study as clinically indicated. The total dose/day of LCIG is composed of 3 individually adjusted doses. The morning dose is administered as a bolus infusion, usually 5 to 10 mL (100 to 200 mg levodopa). The maintenance dose is adjustable in steps of 2 mg/hour (0.1 mL/hour), within a range of 1 to 10 mL/hour (20 to 200 mg levodopa/hour) and is usually 2 to 6 mL/hour (40 to 120 mg levodopa/hour). Participants will be allowed to self-administer extra doses of LCIG to address immediate medical needs, normally 0.5 to 2.0 mL. Participants will receive LCIG until it is commercially available.

Drug: Levodopa-Carbidopa Intestinal Gel (LCIG); LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.; Other Names: Carbidopa-Levodopa Enteral Suspension (CLES); Duopa®; Duodopa®; Device: CADD-Legacy® 1400 ambulatory infusion pump; Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.; Device: Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J); All participants previously had a PEG-J placed in one of the prior LCIG studies.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment-emergent Adverse Events	Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) which started on or after the date of the first LCIG Infusion in this study and within 30 days of the date of the last PEG-J exposure. At least possibly drug-related is defined as TEAEs assessed as having a "Possible" or "Probable" or missing relationship to study drug. Serious AEs included any untoward medical occurrence that: Resulted in death; Was life-threatening; Required inpatient hospitalization or prolongation of an existing hospitalization; Resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect The severity of all AEs was characterized as mild, moderate or severe according to the following definitions: Mild: usually transient and do not interfere with daily activities.; Moderate: low level of inconvenience or concern to the subject, may interfere with daily activities.; Severe: events interrupt the subject's usual daily activity.	From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Device Complications	Device complications include complications with the pump, intestinal tube, PEG-J or stoma.	From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days.
Number of Participants With Sleep Attacks	Participants were asked whether they experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. If yes, participants were asked if they suffered any "bad" outcome or problem from the falling asleep event.	Baseline (final assessment period of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants With Intense Impulsive Behavior	To monitor for the development of intense impulsive behavior the Minnesota Impulsive Disorder Interview (MIDI) was administered. The MIDI is a semi-structured clinical interview assessing pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.	Baseline (final assessment of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants Who Developed Melanoma	A comprehensive assessment for the presence of melanoma was performed at least once a year by a dermatologist.	Once per year during the study; median duration of treatment was 1178 days.
Number of Participants With Treatment-emergent Adverse Events of Special Interest (TE AESI)	Adverse events of special interest (AESIs) were identified using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQ) or company MedDRA queries (CMQs). The AESI in the following categories were identified on the basis of review of the clinical program and postmarketing observations where the treatment system is commercially available.; Procedure and device associated events; Polyneuropathy, included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance; Weight loss; Cardiovascular fatalities; Respiratory tract aspiration including aspiration pneumonia/pneumonitis.	From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Number of Participants With Any Suicidal Ideation or Behavior	The Columbia-Suicide Severity Rating Scale (C-SSRS) was implemented with Protocol Amendment 3 (20 March 2012) in order to assess suicidal behavior and ideation. Suicidal ideation includes the wish to be dead, nonspecific active suicidal thoughts, active ideation without intent to act, active ideation with some intent to act, and active ideation with specific plan or intent. Suicidal behavior includes actual attempts, interrupted attempts, aborted attempts, completed suicide, and preparatory acts or behaviors. The number of participants with affirmative responses on the C-SSRS at any time during the treatment period is reported.	Every 6 months (beginning with implementation of Protocol Amendment 3) until final visit; median duration of treatment was 1178 days.
Number of Participants With Potentially Clinically Significant Vital Sign Values	A vital sign value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.	Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants With Potentially Clinically Significant Hematology Laboratory Values	A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.	Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants With Potentially Clinically Significant Chemistry Laboratory Values	A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding baseline value. ULN = upper limit of normal	Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants With Vitamin Levels Outside of the Normal Range	Special tests for vitamin deficiencies (folic acid, vitamin B6, vitamin B12, methylmalonic acid [MMA], and homocysteine) were implemented with Protocol Amendment 2 (27 July 2011). The number of participants with vitamin levels outside of the normal range at any time post-baseline is reported for each vitamin tested.	Every 6 months (beginning with implementation of Protocol Amendment 2) until final visit; median duration of treatment was 1178 days.
Number of Participants Receiving Concomitant Anti-Parkinson's Disease Medications by Treatment Year	Participants could use oral levodopa-carbidopa for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night, or as rescue medication in case of acute deterioration caused by failure of the LCIG system such as tubes and/or the pump or the onset of an acute illness. The initiation of additional concomitant PD medication was allowed at the discretion of the Investigator if medically indicated.	Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10, > Year 10 (maximum time on treatment was approximately 11.5 years).
Change in Average Daily "Off" Time Based on the Parkinson's Disease Symptom Diary at End of Treatment	The PD symptom diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "Off" time was defined as time when medication had worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A negative change for "off" time indicates improvement. The PD diary assessment was implemented with Protocol amendment 4 (December 2013) for participants at United States (US) sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Average Daily "On" Time Without Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment	The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Non-troublesome dyskinesia does not interfere with function or cause meaningful discomfort. "On" time without troublesome dyskinesia is the sum of "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Average Daily "On" Time With Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment	The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Troublesome dyskinesia interferes with function or causes meaningful discomfort. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). UPDRS Part III consists of 14 questions. Questions 20 - 26 are multi-part questions in that they are evaluated separately for multiple body parts. Counting each of these assessments leads to a total of 27 answers for Part III. The UPDRS Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-Point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The UPDRS total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I - III of the scale. The total score ranges from 0 - 176 with 176 representing the worst (total) disability, and 0 no disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias). The UPDRS Part IV Score is the sum of all answers to the 11 questions that comprise Part IV, 4 of which are measured on a 5-point scale (0 - 4) and 7 which are measured on a 2-point scale (0 - 1). The Part IV score ranges from 0 - 23 with higher scores associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Dyskinesia Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias); and The UPDRS Part IV dyskinesia Score is the sum of Questions 32 (What proportion of the waking day are dyskinesias present?), 33 (How disabling are the dyskinesias? ), and 34 (How painful are the dyskinesias?) on UPDRS Part IV, each of which are measured on a 5-point scale (0-4). The Part IV dyskinesia score ranges from 0 - 12 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Parkinson's Disease Questionnaire (PDQ-39) Scores at End of Treatment	The PDQ-39 is a self-administered questionnaire that comprises 39 items addressing the following eight domains of health that patients consider to be adversely affected by the disease: Mobility (e.g., fear of falling when walking) - 10 questions; Activities of daily living (e.g., difficulty cutting food) - 6 questions; Emotional well-being (e.g., feelings of isolation) - 6 questions; Stigma (e.g., social embarrassment) - 4 questions; Social support - 3 questions; Cognition - 4 questions; Communication - 3 questions; Bodily discomfort - 3 questions Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. The PDQ-39 summary index (range 0-100) includes responses to all 39 items. A negative change indicates improvement.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

Collaborators and Investigators

• Sponsor: AbbVie
• Collaborators: IQVIA, formerly Quintiles

Publications and helpful links

General Publications

• Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018 Jul;33(6):928-936. doi: 10.1002/mds.27338. Epub 2018 Mar 23.

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): November 13, 2009
• Primary Completion (Actual): November 30, 2021
• Study Completion (Actual): November 30, 2021

Study Registration Dates

• First Submitted: April 15, 2008
• First Submitted That Met QC Criteria: April 15, 2008
• First Posted (Estimate): April 17, 2008

Study Record Updates

• Last Update Posted (Actual): December 2, 2022
• Last Update Submitted That Met QC Criteria: November 15, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: Parkinson's Disease; Levodopa; Carbidopa; Dyskinesia; Severe Motor Fluctuations; levodopa/carbidopa intestinal gel
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Immunologic Factors; Dopamine Agonists; Dopamine Agents; Adjuvants, Immunologic; Antiparkinson Agents; Anti-Dyskinesia Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Levodopa; Carbidopa; Carbidopa, levodopa drug combination
• Other Study ID Numbers: S187.3.005; 2008-001329-33 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
• IPD Sharing Time Frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
• IPD Sharing Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No